BTG reveals more Varisolve data ahead of filing
This article was originally published in Scrip
Executive Summary
Specialist healthcare company BTG has reported positive results from VANISH-1, the second and final US pivotal Phase III trial of its varicose vein treatment Varisolve (polidocanol endovenous microfoam; PEM) and reiterated plans to submit a US NDA by the end of the year. However, it said another smaller study called VV017, investigating the use of the product following heat ablation had failed to meet the overall primary objective.